Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • GeNeuro

    - PMLiVE

    Roche shares positive 96-week results for multiple sclerosis candidate fenebrutinib

    The immune-mediated disease affects more than 2.9 million people worldwide

    - PMLiVE

    Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study

    Approximately 2.9 million people worldwide are living with the neurodegenerative disease

    - PMLiVE

    Sanofi’s tolebrutinib shown to delay MS disability progression in phase 3 study

    The BTK inhibitor has been granted FDA priority review to treat the neurodegenerative disease

    - PMLiVE

    Sanofi’s investigational MS treatment tolebrutinib granted FDA priority review

    Approximately 2.9 million people worldwide are living with the neurodegenerative disease

    - PMLiVE

    Merck KGaA’s Mavenclad tablets recommended by NICE for wider MS use

    The neurological disorder affects more than 150,000 people in the UK

    - PMLiVE

    Sanofi’s BTK inhibitor tolebrutinib granted FDA breakthrough designation for MS

    The neurological disorder affects approximately 2.9 million people globally

    - PMLiVE

    Sanofi shares positive late-stage results for investigational BTK inhibitor in progressive MS

    Tolebrutinib is currently being evaluated in various forms of the neurological disorder

    - PMLiVE

    Roche’s injectable Ocrevus Zunovo granted FDA approval to treat relapsing and primary MS

    The subcutaneous formulation has the same twice-yearly dosing schedule as the previously approved intravenous infusion

    - PMLiVE

    Roche shares positive 48-week results for investigational BTK inhibitor in relapsing MS

    Approximately 2.9 million people worldwide are affected by the neurological disease

    - PMLiVE

    Sanofi’s investigational BTK inhibitor tolebrutinib shows promise in phase 3 MS study

    The neurological disorder affects approximately 2.9 million people worldwide

    - PMLiVE

    Roche’s subcutaneous Ocrevus granted MHRA approval to treat relapsing and primary MS

    The NHS said it expects stock of the ten-minute injection to be available in the coming weeks

    - PMLiVE

    Sanofi’s investigational frexalimab shows promise in relapsing MS study

    Approximately 2.9 million people worldwide are affected by the neurological disease

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links